IBDEI0J6 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9005,1,4,0)
 ;;=4^ENDOCRINE/NERV NEO NOS
 ;;^UTILITY(U,$J,358.3,9005,1,5,0)
 ;;=5^239.7
 ;;^UTILITY(U,$J,358.3,9005,2)
 ;;=^267785
 ;;^UTILITY(U,$J,358.3,9006,0)
 ;;=239.5^^38^508^8
 ;;^UTILITY(U,$J,358.3,9006,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9006,1,4,0)
 ;;=4^GU NEOPLASM NOS
 ;;^UTILITY(U,$J,358.3,9006,1,5,0)
 ;;=5^239.5
 ;;^UTILITY(U,$J,358.3,9006,2)
 ;;=^267784
 ;;^UTILITY(U,$J,358.3,9007,0)
 ;;=193.^^38^509^19
 ;;^UTILITY(U,$J,358.3,9007,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9007,1,4,0)
 ;;=4^THYROID CANCER
 ;;^UTILITY(U,$J,358.3,9007,1,5,0)
 ;;=5^193.
 ;;^UTILITY(U,$J,358.3,9007,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,9008,0)
 ;;=240.9^^38^509^4
 ;;^UTILITY(U,$J,358.3,9008,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9008,1,4,0)
 ;;=4^GOITER NOS
 ;;^UTILITY(U,$J,358.3,9008,1,5,0)
 ;;=5^240.9
 ;;^UTILITY(U,$J,358.3,9008,2)
 ;;=^52400
 ;;^UTILITY(U,$J,358.3,9009,0)
 ;;=241.1^^38^509^14
 ;;^UTILITY(U,$J,358.3,9009,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9009,1,4,0)
 ;;=4^MULTINODULAR
 ;;^UTILITY(U,$J,358.3,9009,1,5,0)
 ;;=5^241.1
 ;;^UTILITY(U,$J,358.3,9009,2)
 ;;=^267790
 ;;^UTILITY(U,$J,358.3,9010,0)
 ;;=242.20^^38^509^15
 ;;^UTILITY(U,$J,358.3,9010,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9010,1,4,0)
 ;;=4^MULTINODULAR,TOXIC
 ;;^UTILITY(U,$J,358.3,9010,1,5,0)
 ;;=5^242.20
 ;;^UTILITY(U,$J,358.3,9010,2)
 ;;=^267801
 ;;^UTILITY(U,$J,358.3,9011,0)
 ;;=242.00^^38^509^7
 ;;^UTILITY(U,$J,358.3,9011,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9011,1,4,0)
 ;;=4^GRAVES DISEASE
 ;;^UTILITY(U,$J,358.3,9011,1,5,0)
 ;;=5^242.00
 ;;^UTILITY(U,$J,358.3,9011,2)
 ;;=^267793
 ;;^UTILITY(U,$J,358.3,9012,0)
 ;;=244.9^^38^509^12
 ;;^UTILITY(U,$J,358.3,9012,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9012,1,4,0)
 ;;=4^HYPOTHYROIDISM NOS
 ;;^UTILITY(U,$J,358.3,9012,1,5,0)
 ;;=5^244.9
 ;;^UTILITY(U,$J,358.3,9012,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,9013,0)
 ;;=244.1^^38^509^16
 ;;^UTILITY(U,$J,358.3,9013,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9013,1,4,0)
 ;;=4^POST I-131
 ;;^UTILITY(U,$J,358.3,9013,1,5,0)
 ;;=5^244.1
 ;;^UTILITY(U,$J,358.3,9013,2)
 ;;=^267816
 ;;^UTILITY(U,$J,358.3,9014,0)
 ;;=244.0^^38^509^17
 ;;^UTILITY(U,$J,358.3,9014,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9014,1,4,0)
 ;;=4^POSTSURGICAL HYPOTHYROID
 ;;^UTILITY(U,$J,358.3,9014,1,5,0)
 ;;=5^244.0
 ;;^UTILITY(U,$J,358.3,9014,2)
 ;;=^267814
 ;;^UTILITY(U,$J,358.3,9015,0)
 ;;=246.0^^38^509^10
 ;;^UTILITY(U,$J,358.3,9015,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9015,1,4,0)
 ;;=4^HYPERTHYROCALCITONIN
 ;;^UTILITY(U,$J,358.3,9015,1,5,0)
 ;;=5^246.0
 ;;^UTILITY(U,$J,358.3,9015,2)
 ;;=^267827
 ;;^UTILITY(U,$J,358.3,9016,0)
 ;;=241.0^^38^509^20
 ;;^UTILITY(U,$J,358.3,9016,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9016,1,4,0)
 ;;=4^THYROID NODULE
 ;;^UTILITY(U,$J,358.3,9016,1,5,0)
 ;;=5^241.0
 ;;^UTILITY(U,$J,358.3,9016,2)
 ;;=^83865
 ;;^UTILITY(U,$J,358.3,9017,0)
 ;;=242.10^^38^509^21
 ;;^UTILITY(U,$J,358.3,9017,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9017,1,4,0)
 ;;=4^THYROID NODULE,HOT
 ;;^UTILITY(U,$J,358.3,9017,1,5,0)
 ;;=5^242.10
 ;;^UTILITY(U,$J,358.3,9017,2)
 ;;=^267797
 ;;^UTILITY(U,$J,358.3,9018,0)
 ;;=245.0^^38^509^1
 ;;^UTILITY(U,$J,358.3,9018,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9018,1,4,0)
 ;;=4^ACUTE THYROIDITIS
 ;;^UTILITY(U,$J,358.3,9018,1,5,0)
 ;;=5^245.0
 ;;^UTILITY(U,$J,358.3,9018,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,9019,0)
 ;;=245.2^^38^509^3
 ;;^UTILITY(U,$J,358.3,9019,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9019,1,4,0)
 ;;=4^CHR LYMPHOCYT THYROIDIT
 ;;^UTILITY(U,$J,358.3,9019,1,5,0)
 ;;=5^245.2
 ;;
 ;;$END ROU IBDEI0J6
